On May 18, 2016 The company Innate Pharma and the brokerage firm Gilbert Dupont reported that they have ended the liquidity contract signed on July 27, 2012 (Press release, Innate Pharma, MAY 17, 2016, View Source [SID:1234512539]). The termination is effective from May 13, 2016 after market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As at May 13, 2016 after market, the following assets appeared on the liquidity account:

18,575 shares of Innate Pharma that will be kept in shares portfolio, and
372,807.10 euros in cash.
As a reminder, at December 31, 2015, the following assets appeared on the liquidity account:

22,128 shares of Innate Pharma, and
358,336.72 euros in cash.